BS
Therapeutic Areas
XOMA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VABYSMO® (faricimab) | Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME) | Commercial |
| Iscalimab (CFZ533) | Autoimmune Indications (e.g., Kidney Transplantation, Sjögren's) | Phase 2/Phase 3 |
| Undisclosed BLA-Stage Asset | Undisclosed (Likely Oncology/Immunology) | BLA Submission |